By Cocer Peptides 
1 month ago
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.
The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.
Overview
Osteoarthritis (OA) is a common chronic joint disease characterized by cartilage degeneration, subchondral bone remodeling, and synovial inflammatory responses, significantly impairing patients' quality of life. With the acceleration of population aging, the incidence of OA is on the rise, imposing a burden on society and families.
Figure 1 Comparison of the pathological features of rheumatoid arthritis and osteoarthritis. Rheumatoid arthritis is characterized by an inflammatory process mediated by innate, adaptive, and stromal autoimmune responses.
Cartilage damage is a critical step in the progression of OA. Due to the limited self-repair capacity of cartilage, damage is difficult to heal spontaneously, leading to gradual disease progression. Therefore, identifying effective methods for cartilage damage repair has become a research focus in OA treatment.
Cartalax is a biopharmaceutical specifically designed to promote cartilage damage repair. Its specific composition varies depending on different research and production processes, but it typically contains multiple bioactive factors, extracellular matrix components, and carrier materials. Among these, bioactive factors such as transforming growth factor-β (TGF-β) and insulin-like growth factor-1 (IGF-1) play a crucial role in regulating cartilage cell proliferation, differentiation, and extracellular matrix synthesis. Extracellular matrix components such as collagen and hyaluronic acid provide physical support for chondrocytes and participate in regulating cell adhesion, migration, and signal transduction. Carrier materials serve to encapsulate and sustain-release bioactive components, ensuring their continuous efficacy at the injury site.
The Role of Cartalax in Cartilage Injury Repair
(1) Promoting Chondrocyte Proliferation and Differentiation
Bioactive factors in Cartalax, such as TGF-β and IGF-1, activate signaling pathways within chondrocytes, promoting cell cycle progression and enabling chondrocytes to transition from the quiescent phase to the proliferative phase. TGF-β binds to cell surface receptors to activate the Smad signaling pathway, regulating the expression of cell cycle-related proteins, thereby promoting DNA synthesis and cell division in chondrocytes. IGF-1, on the other hand, inhibits chondrocyte apoptosis through the PI3K-Akt and MAPK signaling pathways while promoting cell proliferation, increasing the number of chondrocytes, and providing an adequate cellular source for cartilage repair.
During the progression of osteoarthritis, the phenotype of chondrocytes is prone to change, characterized by reduced synthesis of chondrospecific matrix components such as type II collagen and proteoglycans, and increased synthesis of type I collagen and matrix metalloproteinases (MMPs), leading to cartilage tissue degeneration. Cartalax can maintain the normal phenotype of chondrocytes by regulating intracellular signal transduction and gene expression, maintains the normal phenotype of chondrocytes. TGF-β can upregulate the expression of the SOX9 gene, which is a key transcription factor that promotes the gene transcription of type II collagen and proteoglycans, thereby maintaining the ability of chondrocytes to synthesize cartilage-specific matrix components. Certain components in Cartalax can also inhibit the expression of MMPs, reduce the degradation of the extracellular matrix, and protect the integrity of cartilage tissue.
(2) Regulation of extracellular matrix metabolism
The extracellular matrix is an important component of cartilage tissue, primarily composed of collagen, proteoglycans, and elastic fibers. Cartalax promotes the synthesis of these extracellular matrix components by activating anabolic signaling pathways within chondrocytes. In addition to the aforementioned TGF-β-mediated promotion of type II collagen and proteoglycan synthesis, other growth factors in Cartalax, such as fibroblast growth factor (FGF), can also act synergistically to stimulate chondrocytes to synthesize more extracellular matrix. FGF enhances the protein synthesis capacity within chondrocytes, promoting the synthesis and secretion of large molecules such as collagen and proteoglycans, thereby increasing the content of the extracellular matrix and improving the biomechanical properties of cartilage.
During cartilage injury repair, the remodeling of the extracellular matrix is a dynamic process. Cartalax not only promotes the synthesis of the extracellular matrix but also regulates its remodeling process. It achieves this by regulating the balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). Cartalax inhibits the activity of MMPs, reducing excessive degradation of the extracellular matrix; it promotes the expression of TIMPs, enhancing their inhibitory effect on MMPs, thereby maintaining a relative balance between the synthesis and degradation of the extracellular matrix, which is conducive to the orderly repair and remodeling of cartilage tissue.
(3) Anti-inflammatory effects
Inflammatory responses play a significant role in the onset and progression of OA. Cartalax possesses certain anti-inflammatory properties and can regulate the expression of inflammatory cytokines. In the inflammatory microenvironment, Cartalax can inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), while upregulating the expression of anti-inflammatory cytokines such as interleukin-10 (IL-10), thereby alleviating local joint inflammation and creating a favorable microenvironment for cartilage repair.
Application of Cartalax in the Treatment of Osteoarthritis
(1) Animal Experiment Studies
In animal experiments, researchers established various OA animal models, such as the rat OA model induced by anterior cruciate ligament transection (ACLT) and the rabbit OA model induced by papain, to evaluate the efficacy of Cartalax in cartilage damage repair. Experimental results showed that after Cartalax intervention, histological analysis revealed significant improvements in joint cartilage surface smoothness, cellular structure, and extracellular matrix components. The cartilage damage score in the experimental group was significantly reduced, indicating that Cartalax effectively reduces the severity of cartilage damage.
Immunohistochemical and molecular biological analyses revealed elevated expression levels of cartilage-specific markers and reduced expression levels of degradative enzymes such as MMPs in the Cartalax-treated group, further confirming its role in promoting cartilage repair and regulating extracellular matrix metabolism.
(2) Clinical Application Exploration
Although Cartalax is still in the exploratory stage for clinical application, some preliminary clinical studies have been reported. Cartalax is primarily indicated for patients with mild to moderate osteoarthritis, especially those with confirmed cartilage damage. For early-stage osteoarthritis, where cartilage damage is still reversible, Cartalax can effectively slow disease progression and repair cartilage damage by promoting chondrocyte proliferation, regulating extracellular matrix metabolism, and reducing inflammatory responses. Cartalax can also be used as an adjunct to surgical treatment, applied after arthroscopic surgery or cartilage repair surgery to promote the healing and repair of cartilage tissue.
Conclusion
In summary, Cartalax demonstrates significant potential in repairing cartilage damage in the treatment of osteoarthritis. From a mechanism of action perspective, it promotes cartilage cell proliferation and differentiation, regulates extracellular matrix metabolism, and exerts anti-inflammatory effects, thereby repairing and protecting damaged cartilage from multiple angles.
Sources
[1] Hu N, Qiu J, Xu B, et al. The Role of Cartilage Stem/Progenitor Cells in Cartilage Repair in Osteoarthritis[J]. Current Stem Cell Research & Therapy, 2023,18(7):892-903.DOI:10.2174/1574888X17666221006113739.
[2] McClurg O, Tinson R, Troeberg L. Targeting Cartilage Degradation in Osteoarthritis[J]. Pharmaceuticals, 2021,14(2).DOI:10.3390/ph14020126.
[3] Tanideh N, Borzooeian G, Lotfi M, et al. Novel strategy of cartilage repairing via application of P. atlantica with stem cells and collagen[J]. Artificial Organs, 2021,45(11):1405-1421.DOI:10.1111/aor.14026.
[4] To K, Romain K, Mak C, et al. The Treatment of Cartilage Damage Using Human Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Systematic Review of in vivo Studies[J]. Frontiers in Bioengineering and Biotechnology, 2020,8:580.DOI:10.3389/fbioe.2020.00580.
[5] Macfarlane E, Seibel M J, Zhou H. Arthritis and the role of endogenous glucocorticoids[J]. Bone Research, 2020,8(1):33.DOI:10.1038/s41413-020-00112-2.
[6] Huang L J, Chen W P. Astaxanthin ameliorates cartilage damage in experimental osteoarthritis[J]. Modern Rheumatology, 2015,25(5):768-771.DOI:10.3109/14397595.2015.1008724.
Product available for research use only:
